厄贝沙坦联合辛伐他汀治疗充血性心衰的疗效观察

目的观察厄贝沙坦联合辛伐他汀治疗充血性心衰(CHF)的疗效。方法将120例NYHA心功能分级为Ⅱ～Ⅲ级的CHF患者随机分为厄贝沙坦联合辛伐他汀治疗组、辛伐他汀治疗组和常规治疗对照组各40例,随访180天,观察治疗前后NYHA心功能分级,同时超声心动图检测左室舒张末期内径(LVED)、左室收缩末期内径(LVES)、左室射血分数(LVEF)及E/A比值,并测定B型利钠肽(BNP)水平等指标的变化来评估治疗效果。结果 180天后,辛伐他汀对照组与常规治疗组比较,心功能分级、LVEF、LVES、LVED、E/A无统计学意义(P≥0.05),厄贝沙坦联合辛伐他汀治疗组心功能分级、LVEF、LVES、LVED、E/A、BNP较对照组存在统计学意义(P<0.01)。结论厄贝沙坦联合辛伐他汀治疗充血性心衰比单用辛伐他汀有更好的临床疗效。

The clinical study of Irbesartan and Simvastatin on treating chronic congestive heart failure

Objective To investigate the effects of Irbesartan and Simvastatin on patients suffering from chronic congestive heart failure （CHF）. Methods 120 CHF patients were randomly derided into routine control group,Irbesartan joint Simvastatin group and Simvastatin group. 180 days later, the changes of left ventricular end diastolic diameter （LVED） ,left ventricular end contract surface （LVES）,left ventricular eiection fraction LVEF,and cardiac function（NY- HA class）were observed before and after therapy. At the same time the concentration of brain natriuretic peptide （BNP） were determined with chemiluminescent method. Results There was a significant statistical diferences in NYHA,LVED, LVES,LVEF,E/A and BNP between Irbesartan joint Simvastatin group and routine control group （P〈0.01）, but not between Irbesartan joint Simvastatin group and Simvastatin group. Conclusion Irbesartan joint Simvastatin is more effec- tive than Simvastatin in treating patients with CHF.